Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma

Published:2009-10 Issue:4 Volume:68 Page:561-573
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Ternant David,Hénin Emilie,Cartron Guillaume,Tod Michel,Paintaud Gilles,Girard Pascal

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2009.03494.x/fullpdf

Reference40 articles.

1. Rituximab anti-CD20 monoclonal antibody for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998

2. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma;Maloney;Blood,1997

3. Pharmacokinetics of rituximab and its clinical use: thought for the best use?;Cartron;Crit Rev Oncol Hematol,2007

4. Rituximab in the treatment of refractory follicular lymphoma - six doses are better than four;Aviles;J Hematother Stem Cell Res,2001

5. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study;Bremer;Anticancer Drugs,2003

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules;Atkinson's Principles of Clinical Pharmacology;2022

2. Obinutuzumab‐related adverse events: A systematic review and meta‐analysis;Hematological Oncology;2020-12-10

3. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited;Clinical Pharmacokinetics;2019-10-05

4. A tale of two antibodies: obinutuzumabversusrituximab;British Journal of Haematology;2018-05-09

5. The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis;Annals of Hematology;2016-07-19